Approved for use in patients 2 and older to treat two types of epileptic syndromes: Dravet syndrome, a rare genetic dysfunction of the brain that begins in the first year of life, and Lennox-Gastaut syndrome, a form of epilepsy with multiple types of seizures that begins in early childhood, usually between ages 3 and 5.
https://www.cnn.com/…/marijuana-drug-epidiolex-…/index.html…
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm